Captrust Financial Advisors Maxcyte, Inc. Transaction History

Captrust Financial Advisors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.69 - $5.35 $39,881 - $57,822	-10,808 Reduced 4.93%	208,448 $956,000
Q1 2023 May 15, 2023	BUY	$4.03 - $5.89 $154,941 - $226,452	38,447 Added 21.26%	219,256 $1.09 Million
Q4 2022 Feb 15, 2023	BUY	$4.92 - $7.4 $396,330 - $596,107	80,555 Added 80.35%	180,809 $987,000
Q3 2022 Nov 16, 2022	BUY	$4.52 - $6.51 $452,917 - $652,321	100,203 Added 196476.47%	100,254 $652,000
Q2 2022 Aug 16, 2022	BUY	$3.59 - $6.81 $50 - $95	14 Added 37.84%	51 $0
Q1 2022 May 16, 2022	BUY	$5.26 - $10.84 $194 - $401	37 New	37 $0
Q4 2021 Feb 14, 2022	SELL	$8.87 - $12.94 $1,516 - $2,212	-171 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$12.21 - $17.2 $2,087 - $2,941	171 New	171 $2,000

118

65M

600

2.7K

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $368M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.